Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

This Cancer Biotech Stock Just Averted A Patent Disaster In Europe

quotesVery interesting …quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

AZ’ Imfinzi Fails In Head And Neck Cancer Trial

quotesOnce again, despite our hopes, and the imagination of the public, that a magic-bullet immunotherapy …quotes

member-photo

Richard Goldberg, MD

Director WVU Cancer Institute
Director of Cancer Signature Program
Laurence S. and Jean J. DeLynn Chair of Oncology

Comments

Study Examines 'Watch-And-Wait' Approach for People with Rectal Cancer

quotesThis is a very interesting study that opens the door to prospective investigation of a randomized tr…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

Azar Announces Mandatory Oncology Payment Model Is Coming

quotesThis is yet another mandatory experiment on cancer patient care that is terrible medicine and uncons…quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

Facing Criticism, CVS May Modify Its New Cost-Effectiveness Program For Covering Some Drugs

quotes C-VICER: CVS Embraces ICER We have reached a v…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

Men with Prostate Cancer Are Willing To Accept Lower Survival Odds To Avoid Incontinence, Impotence And Repeat Treatments

quotesThis study provides an important aggregate assessment of how men weigh survival and adverse effects …quotes

member-photo

H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Comments

Genentech: FDA Approves Tecentriq in Combination for Some Lung Cancer Patients

quotesWhile it's nice to have a new approval, this is also a setting in which the IMpower150 regimen offer…quotes

member-photo

Winston Wong, PharmD

President, W-Squared Group

Comments

Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

quotesThis piece is a great example of a pathway program in process. Clinical pathways are not meant to b…quotes

member-photo

Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst

Comments

U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

quotesI am excited to be joining the editorial board on OBR; I have been a fan of the publication since it…quotes

member-photo

Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One

No comments to show!

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

Reducing Time to Chemo Administration in an Inpatient Hematology Malignancy Unit

quotesIn contrast, chemotherapy initiation in the outpatient setting is being continually delayed due to p…quotes

member-photo

Jeff Patton, M.D.

CEO
Tennessee Oncology

Comments

First Opinion: Physicians Aren’t ‘Burning Out.’ They’re Suffering From Moral Injury

quotesI found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

Medicare Costs Drop As Humana Shifts Doctors To Value-Based Models

quotesOK so I went into this with an negative attitude but actually to give the devil his due they actual…quotes

member-photo

William Harwin MD

Florida Cancer Specialists
President and Managing Partner

Comments

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

quotesLike the data…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Benefit of LDR Brachytherapy In Patients With Early-Stage Prostate Cancer Is Still Unclear

quotesIt's very challenging to run clinical trials when patients are randomized to very different treatmen…quotes